Identification of β2-microglobulin as a urinary biomarker for chronic allograft nephropathy using proteomic methods
Files in This Item:
|Johnston et al PRCA2011.pdf||281.03 kB||Adobe PDF||Download|
|Title:||Identification of β2-microglobulin as a urinary biomarker for chronic allograft nephropathy using proteomic methods||Authors:||Johnston, Olwyn
Gallagher, William M.
Maguire, Patricia B.
Ryan, Michael P.
Conlon, Peter J.
|Permanent link:||http://hdl.handle.net/10197/3015||Date:||Aug-2011||Online since:||2011-07-12T15:35:43Z||Abstract:||Chronic allograft nephropathy (CAN) remains the leading cause of renal graft loss after the first year following renal transplantation. This study aimed to identify novel urinary proteomic profiles, which could distinguish and predict CAN in susceptible individuals. Experimental Design: The study included 34 renal transplant patients with histologically proven CAN and 36 patients with normal renal transplant function. High-throughput proteomic profiles were generated from urine samples with three different ProteinChip arrays by surface-enhanced laser-desorption/ionization time-of-flight mass spectrometry (SELDI-TOF-MS). Following SELDI a biomarker pattern software analysis was performed which led to the identification of a novel biomarker pattern that could distinguish patients with CAN from those with normal renal function. Results: An 11.7 kDa protein identified as β2 microglobulin was the primary protein of this biomarker pattern, distinguishing CAN from control patients (ROC = 0.996). SELDI-TOF-MS comparison of purified β2 microglobulin protein and CAN urine demonstrated identical 11.7 kDa protein peaks. Significantly higher concentrations of β2 microglobulin were found in the urine of patients with CAN compared to the urine of normal renal function transplant recipients (p<0.001). Conclusions and clinical relevance: Whilst further validation in a larger more diverse patient population is required to determine if this β2 microglobulin protein biomarker will provide a potential means of diagnosing CAN by non-invasive methods in a clinical setting, this study clearly shows a capability to stratify control and disease patients.||Funding Details:||Higher Education Authority
European Research Council
Health Research Board
|Type of material:||Journal Article||Publisher:||Wiley||Journal:||Proteomics - Clinical Applications||Volume:||5||Issue:||7-8||Start page:||422||End page:||431||Copyright (published version):||2011 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim||Keywords:||CAN; β2-microglobulin; ROC; SELDI-TOF MS; Biomarkers; Renal transplantation||Subject LCSH:||Kidneys--Diseases
|DOI:||10.1002/prca.201000160||Other versions:||http://dx.doi.org/10.1002/prca.201000160||Language:||en||Status of Item:||Peer reviewed|
|Appears in Collections:||Conway Institute Research Collection|
Biomolecular and Biomedical Science Research Collection
Show full item record
Page view(s) 10195
This item is available under the Attribution-NonCommercial-NoDerivs 3.0 Ireland. No item may be reproduced for commercial purposes. For other possible restrictions on use please refer to the publisher's URL where this is made available, or to notes contained in the item itself. Other terms may apply.